127 related articles for article (PubMed ID: 1372353)
21. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008
[TBL] [Abstract][Full Text] [Related]
22. Random expression of human immunodeficiency virus-1 (HIV-1) p17 (epitopes) on the surface of the HIV-1-infected cell.
Ota A; Liu X; Fujio H; Sakato N; Ueda S
Hybridoma; 1998 Feb; 17(1):73-5. PubMed ID: 9523241
[TBL] [Abstract][Full Text] [Related]
23. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
24. A prospective study on correlation between the decrease in anti-P17 antibody level and progression to AIDS in asymptomatic carriers of HIV.
Choudhury AM; Yamada O; Wakamiya N; Kurimura T
Microbiol Immunol; 1992; 36(8):833-40. PubMed ID: 1474934
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
[TBL] [Abstract][Full Text] [Related]
26. Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine.
Pisarev VM; Parajuli P; Mosley RL; Sublet J; Kelsey L; Sarin PS; Zimmerman DH; Winship MD; Talmadge JE
Int J Immunopharmacol; 2000 Nov; 22(11):865-76. PubMed ID: 11090695
[TBL] [Abstract][Full Text] [Related]
27. A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course.
Chargelegue D; Colvin BT; O'Toole CM
AIDS; 1993 Nov; 7 Suppl 2():S87-90. PubMed ID: 7909231
[TBL] [Abstract][Full Text] [Related]
28. Identification of a potent synthetic HIV1 immunogen compromising gag-P24 tandem T- and B-cell epitopes.
Chong P; Sia C; Sydor M; Klein M
FEBS Lett; 1990 May; 264(2):231-4. PubMed ID: 1694143
[TBL] [Abstract][Full Text] [Related]
29. Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice.
Sarin PS; Talmadge JE; Heseltine P; Murcar N; Gendelman HE; Coleman R; Kelsey L; Beckner S; Winship D; Kahn J
Vaccine; 1999 Jan; 17(1):64-71. PubMed ID: 10078609
[TBL] [Abstract][Full Text] [Related]
30. Characterization of antibodies reacting with HIV gag proteins occasionally found in the serum of non-infected subjects.
Bürgisser P; Frei PC
Clin Exp Immunol; 1991 Aug; 85(2):219-23. PubMed ID: 1713811
[TBL] [Abstract][Full Text] [Related]
31. A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.
Chargelegue D; O'Toole CM; Colvin BT
Clin Exp Immunol; 1993 Sep; 93(3):331-6. PubMed ID: 8370162
[TBL] [Abstract][Full Text] [Related]
32. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
33. A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE.
Buratti E; Tisminetzky SG; D'Agaro P; Baralle FE
J Virol; 1997 Mar; 71(3):2457-62. PubMed ID: 9032383
[TBL] [Abstract][Full Text] [Related]
34. Immune complex transfer enzyme immunoassay for antibody IgM to HIV-1 p17 antigen.
Hashida S; Ishikawa S; Nishikata I; Hashinaka K; Oka S; Ishikawa E
J Clin Lab Anal; 1998; 12(6):329-36. PubMed ID: 9850183
[TBL] [Abstract][Full Text] [Related]
35. Optimal conditions of immune complex transfer enzyme immunoassays for antibody IgGs to HIV-1 using recombinant p17, p24, and reverse transcriptase as antigens.
Hashida S; Ishikawa S; Hashinaka K; Nishikata I; Oka S; Shimada K; Saito A; Takamizawa A; Shinagawa H; Ishikawa E
J Clin Lab Anal; 1998; 12(2):98-107. PubMed ID: 9524294
[TBL] [Abstract][Full Text] [Related]
36. Disappearance of anti-p17 correlates with successful isolation of human immunodeficiency virus and deterioration in clinical status.
Kageyama S; Kurimura T
Int J STD AIDS; 1990 Mar; 1(2):129-31. PubMed ID: 2092788
[TBL] [Abstract][Full Text] [Related]
37. Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus.
Willer A; Achour A; Mbika JP; Laaroubi K; Lachgar A; Nihrane A; Picard O; Naylor PH; Sarin PS; Goldstein AL
Biomed Pharmacother; 1992; 46(8):359-65. PubMed ID: 1292646
[TBL] [Abstract][Full Text] [Related]
38. Flt3 ligand and conjugation to IL-1beta peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine.
Pisarev VM; Parajuli P; Mosley RL; Chavez J; Zimmerman D; Winship D; Talmadge JE
Vaccine; 2002 May; 20(17-18):2358-68. PubMed ID: 12009292
[TBL] [Abstract][Full Text] [Related]
39. Characterization of murine monoclonal antibodies directed against the submembrane protein p17 of HIV-1.
Niedrig M; Harthus HP; Bröker M; Meloen R; Gelderblom H; Pauli G
Hybridoma; 1993 Aug; 12(4):431-9. PubMed ID: 7503941
[TBL] [Abstract][Full Text] [Related]
40. Epitope mapping of the HIV-1 gag region with monoclonal antibodies.
Hinkula J; Rosen J; Sundqvist VA; Stigbrand T; Wahren B
Mol Immunol; 1990 May; 27(5):395-403. PubMed ID: 1694957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
